Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Xia, Xi ^a,b   Ma, Quanfu ^b   Li, Xiao ^b,c   Ji, Teng ^b   Chen, Pingbo ^b   Xu, Hongbin ^b,d   Li, Kezhen ^b   Fang, Yong ^b   Weng, Danhui ^b   Weng, Yanjie ^b   Liao, Shujie ^b   Han, Zhiqiang ^b   Liu, Ronghua ^b   Zhu, Tao ^b   Wang, Shixuan ^b   Xu, Gang ^b   Meng, Li ^b   Zhou, Jianfeng ^b   Ma, Ding ^b  

^a Shenzhen Nanshan People s Hospital and the 6th Affiliated Hospital of Shenzhen University Medical School   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d SHENZHEN PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN KINASE B BETA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN KINASE B;

ADULT; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CLINICAL ARTICLE; CYTOPLASM; DRUG EXPOSURE; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; OVARY CANCER; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; CELL PROLIFERATION; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; GENE TRANSLOCATION; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; TRANSLOCATION, GENETIC;

EID: 80053173452     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-399     Document Type: Article

References (43)

1. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol 2009, 472:413-37. 10.1007/978-1-60327-492-0_20, 19107446.
2. Chien JR, Aletti G, Bell DA, Keeney GL, Shridhar V, Hartmann LC. Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J Cell Biochem 2007, 102:1117-29. 10.1002/jcb.21552, 17879946.
3. Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M, Tsang BK. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat 2002, 5:31-46.
4. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992, 89:3070-4. 10.1073/pnas.89.7.3070, 48805, 1348364.
5. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1998, 241:1813-1815.
6. Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991, 87:772-777. 10.1172/JCI115080, 329864, 1999494.
7. Hajra KM, Tan L, Liu JR. Defective apoptosis underlies chemoresistance in ovarian cancer. Adv Exp Med Biol 2008, 622:197-208. 10.1007/978-0-387-68969-2_16, 18546629.
8. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 2003, 63:7081-7088.
9. Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK, Ngan HY. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 2008, 29:1742-50. 10.1093/carcin/bgn167, 18632752.
10. Fraser M, Bai T, Tsang BK. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 2008, 122:534-546. 10.1002/ijc.23086, 17918180.
11. Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, Meng L, Wang S, Lu Y, Ma D. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 2008, 261:108-19. 10.1016/j.canlet.2007.11.022, 18171600.
12. Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J, Xu G, Lu Y, Wang S, Ma D. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett 2008, 271:260-71. 10.1016/j.canlet.2008.06.012, 18657898.
13. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, Mumper RJ. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009, 69:3918-26. 10.1158/0008-5472.CAN-08-2747, 2758164, 19383919.
14. Xiao L, Gao R, Lu S, Lu MS, Liang ML, Ren LR, Wang ZH. Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel. Zhonghua Fu Chan Ke Za Zhi 2007, 42:412-6.
15. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-16. 10.1016/0092-8674(93)90499-G, 8242751.
16. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med 1995, 1:1052-6. 10.1038/nm1095-1052, 7489362.
17. Komiya T, Hosono Y, Hirashima T, Masuda N, Yasumitsu T, Nakagawa K, Kikui M, Ohno A, Fukuoka M, Kawase I. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 1997, 3:1831-5.
18. Zirbes TK, Baldus SE, Moenig SP, Nolden S, Kunze D, Shafizadeh ST, Schneider PM, Thiele J, Hoelscher AH, Dienes HP. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer 2000, 89:14-8. 10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L, 10719725.
19. Lu X, Toki T, Konishi I, Nikaido T, Fujii S. Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. Cancer 1998, 82:2409-17. 10.1002/(SICI)1097-0142(19980615)82:12<2409::AID-CNCR15>3.0.CO;2-T, 9635534.
20. Kapranos N, Stathopoulos GP, Manolopoulos L, Kokka E, Papadimitriou C, Bibas A, Yiotakis J, Adamopoulos G. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res 2001, 21:521-8.
21. Ferrandina G, Stoler A, Fagotti A, Fanfani F, Sacco R, De Pasqua A, Mancuso S, Scambia G. p21WAF1/CIP1 protein expression in primary ovarian cancer. Int J Oncol 2000, 17:1231-5.
22. Barboule N, Baldin V, JOzan S, Vidal S, Valette A. Increased level of p21 in human ovarian tumors is associated with increased expression of cdk2, cyclin A and PCNA. Int J Cancer 1998, 76:891-6. 10.1002/(SICI)1097-0215(19980610)76:6<891::AID-IJC20>3.0.CO;2-4, 9626358.
23. Cheung TH, Lo KW, Yu MM, Yim SF, Poon CS, Chung TK, Wong YF. Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma. Cancer Lett 2001, 172:93-8. 10.1016/S0304-3835(01)00624-3, 11595134.
24. Bae DS, Cho SB, Kim YJ, Whang JD, Song SY, Park CS, Kim DS, Lee JH. Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus. Gynecol Oncol 2001, 81:341-7. 10.1006/gyno.2001.6196, 11371120.
25. Ceccarelli C, Santini D, Chieco P, Lanciotti C, Taffurelli M, Paladini G, Marrano D. Quantitative p21(waf-1)/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators. Int J Cancer 2001, 95:128-34. 10.1002/1097-0215(20010320)95:2<128::AID-IJC1022>3.0.CO;2-D, 11241324.
26. Sarbia M, Gabbert HE. Modern pathology: prognostic parameters in squamous cell carcinoma of the esophagus. Recent Results Cancer Res 2000, 155:15-27. 10.1007/978-3-642-59600-1_2, 10693235.
27. Besson A, Assoian RK, Roberts JM. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?. Nat Rev Cancer 2004, 4:948-55. 10.1038/nrc1501, 15573116.
28. Kumar R, Hung MC. Signaling intricacies take center stage in cancer cells. Cancer Res 2005, 65:2511-5. 10.1158/0008-5472.CAN-05-0189, 15805240.
29. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001, 3:245-52. 10.1038/35060032, 11231573.
30. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501. 10.1038/nrc839, 12094235.
31. Roninson IB. Oncogenic functions of tumor suppressor p21 (Waf1/Cip1/Sdi1): association with cell senescence and tumor-promoting activities of stromal fibroblasts. Cancer Lett 2002, 179:1-14. 10.1016/S0304-3835(01)00847-3, 11880176.
32. Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, Zhou BP, Hung MC. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 2004, 10:3815-24. 10.1158/1078-0432.CCR-03-0527, 15173090.
33. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res 2003, 5:R242-9. 10.1186/bcr654, 314414, 14580260.
34. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004, 96:487-8.
35. Weng D, Song X, Xing H, Ma X, Xia X, Weng Y, Zhou J, Xu G, Meng L, Zhu T, Wang S, Ma D. Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Lett 2009, 273:257-65. 10.1016/j.canlet.2008.08.027, 18842333.
36. Zhang J, Attar E, Cohen K, Crumpacker C, Scadden D. Silencing p21(Waf1/Cip1/Sdi1) expression increases gene transduction efficiency in primitive human hematopoietic cells. Gene Ther 2005, 12:1444-52. 10.1038/sj.gt.3302544, 15877047.
37. Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA, de Jong S. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 2010, 120:3594-605. 10.1172/JCI41939, 2947220, 20811155.
38. Hamilton TC, Lai GM, Rothenberg ML, Fojo AT, Young RC, Ozols RF. Mechanisms of resistance to cisplatin and alkylating agents. Cancer Treat Res 1989, 48:151-69. 10.1007/978-1-4613-1601-5_10, 2577136.
39. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001, 61:1862-8.
40. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-74. 10.1016/j.cell.2007.06.009, 2756685, 17604717.
41. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23:5853-7. 10.1038/sj.onc.1207721, 15208673.
42. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV, Cheng JQ. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000, 19:2324-30. 10.1038/sj.onc.1203598, 10822383.
43. Héron-Milhavet L, Franckhauser C, Rana V, Berthenet C, Fisher D, Hemmings BA, Fernandez A, Lamb NJ. Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol 2006, 26:8267-80. 10.1128/MCB.00201-06, 1636765, 16982699.